-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Friday, Denali Therapeutics Regains Full Rights To DNL593 After Takeda Terminates Collaboration, Phase 1/2 FTD-GRN Trial Results Expected By End Of 2026

Benzinga·04/06/2026 07:03:53
Listen to the news
  • Denali plans to continue clinical development of DNL593, which is designed to deliver progranulin to the brain using TransportVehicle™ technology
  • Results from ongoing Phase 1/2 study in patients with FTD-GRN expected by the end of 2026